EMA: CHMP Positive Opinion: Colchicine Agepha Pharma

EMA21 May 2026CHMP Positive Opinion● 6/10i

EMA: CHMP Positive Opinion: Colchicine Agepha Pharma

Agepha Pharma s.r.o.

CHMP issued a positive opinion for Colchicine Agepha Pharma to reduce myocardial infarction, stroke, coronary revascularization, and cardiovascular death risk in people with atherosclerotic disease or multiple cardiovascular risk factors on May 21, 2026. This represents a new marketing authorization application for the anti-inflammatory drug in cardiovascular prevention. Agepha Pharma gains access to the growing European cardiovascular prevention market, competing against established lipid-lowering therapies and newer anti-inflammatory approaches. The approval follows established precedent from colchicine's proven cardiovascular benefits in landmark trials.

Strategic Signal

European cardiologists now have access to a cost-effective anti-inflammatory option for secondary cardiovascular prevention, potentially shifting treatment algorithms beyond statins and PCSK9 inhibitors. NICE and other HTA bodies will likely evaluate colchicine favorably given its low cost profile compared to newer cardiovascular therapies. This creates pricing pressure on premium anti-inflammatory approaches and may accelerate guideline adoption of inflammation targeting in cardiovascular prevention across EU markets.

CardiovascularAgepha Pharma

Original Abstract

EMA action: CHMP Positive Opinion | Medicine: Colchicine Agepha Pharma | INN (active substance): colchicine | Decision date: May 21, 2026 | Sponsor: Agepha Pharma s.r.o. | EMA product number: EMEA/H/C/006653 | Indication: Indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in patients with atherosclerotic disease or with multiple risk factors for cardiovascular disease. | Geography: European Union (EMA / EC)

View original source ↗

Related signals

Strategic Signal

Clinical Trial17 Apr 2026Phase 3High impact● 8/10i

A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Phase 3 open-label trial compared once-daily oral orforglipron versus insulin glargine in people with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study enrolled 2,749 participants with primary endpoint of time to first major adverse cardiovascular event, completed in March 2026. Eli Lilly is positioning orforglipron as a cardiovascular outcomes option in high-risk populations, directly competing with established insulin therapy in this indication. This represents the first cardiovascular outcomes trial for orforglipron following its April 2026 FDA approval for type 2 diabetes.

GLP-1Type 2 diabetesWeight lossCardiovascularEli Lilly

Strategic Signal

PubMed28 Mar 2026JAMA cardiologyHigh impact● 8/10i

Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.

Tirzepatide reduced a 6-component cardiorenal composite endpoint by 16% versus dulaglutide (23.7% vs 27.4%, HR 0.84) in people with type 2 diabetes and cardiovascular disease. Post hoc analysis of SURPASS-CVOT double-blind RCT, 13,165 patients, median 46.9 months follow-up. This provides the first head-to-head cardiorenal comparison between tirzepatide and a GLP-1 agonist in high-risk cardiovascular patients, extending beyond the primary non-inferiority finding. Gastrointestinal adverse events were higher with tirzepatide (42.5% vs 35.9%).

GLP-1CardiovascularKidneyType 2 diabetesDrug comparisonsEli Lilly Novo Nordisk

Strategic Signal

Clinical Trial12 Mar 2026Phase 3High impact● 8/10i

The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease

Phase 3 cardiovascular outcomes trial evaluating CagriSema (cagrilintide + semaglutide 2.4 mg/2.4 mg) versus placebo in people with established cardiovascular disease. 7,101 participants enrolled with up to 4.5 years follow-up, measuring time to first 3-point MACE (cardiovascular death, non-fatal MI, non-fatal stroke). Novo Nordisk is testing whether their dual amylin/GLP-1 combination can deliver cardiovascular benefits beyond current GLP-1 monotherapy in high-risk populations. This represents the first major cardiovascular outcomes trial for a dual incretin/amylin combination therapy.

GLP-1CardiovascularWeight lossNovo Nordisk

Strategic Signal

Clinical Trial12 Jan 2026Phase 3High impact● 8/10i

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity

Phase 3 cardiovascular outcomes trial testing tirzepatide versus placebo in 15,374 adults with obesity, measuring time to first major adverse cardiovascular event (death, MI, stroke, coronary revascularization, or heart failure). The randomized, double-blind, placebo-controlled study completed enrollment with expected results in October 2027. This represents Eli Lilly's bid to establish tirzepatide's cardiovascular benefits in obesity, directly competing with Novo Nordisk's Wegovy which gained MACE indication approval in March 2024. The massive enrollment suggests Lilly is positioning for a broad obesity cardiovascular claim to differentiate from Novo's narrower obesity plus established CVD indication.

GLP-1Weight lossCardiovascularEli Lilly Novo Nordisk